ContextVision (CONTX) Aperçu de l'action
ContextVision AB (publ), société de logiciels, fournit des services d'analyse d'images et d'imagerie pour les systèmes médicaux en Asie, en Europe et en Amérique. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 0/6 |
| Performances passées | 1/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
CONTX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ContextVision AB (publ) Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | NOK 3.11 |
| Plus haut sur 52 semaines | NOK 4.94 |
| Plus bas sur 52 semaines | NOK 2.70 |
| Bêta | 0.21 |
| Variation sur 1 mois | -21.66% |
| Variation sur 3 mois | 0.65% |
| Variation sur 1 an | -36.53% |
| Variation sur 3 ans | -61.12% |
| Variation sur 5 ans | -83.43% |
| Évolution depuis l'introduction en bourse | -15.95% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.Mise à jour du récit • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.Mise à jour du récit • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.Recent updates
Mise à jour du récit • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.Mise à jour du récit • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.Mise à jour du récit • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.Mise à jour du récit • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.Mise à jour du récit • Feb 24
CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.Mise à jour du récit • Feb 09
CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).Mise à jour du récit • Jan 25
CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).Mise à jour du récit • Jan 10
CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.Mise à jour du récit • Dec 25
CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.Mise à jour du récit • Dec 11
CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.Mise à jour du récit • Nov 27
CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.Article d’analyse • Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...Mise à jour du récit • Nov 12
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.Article d’analyse • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Article d’analyse • Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...Article d’analyse • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Mise à jour du récit • Aug 09
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).Article d’analyse • May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...Article d’analyse • Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
Nouveau récit • Feb 26
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.Article d’analyse • Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...Article d’analyse • Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...Article d’analyse • Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...Article d’analyse • Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...Article d’analyse • Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...Article d’analyse • Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...Article d’analyse • Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...Article d’analyse • Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...Rendement pour les actionnaires
| CONTX | NO Healthcare Services | NO Marché | |
|---|---|---|---|
| 7D | -6.3% | 2.3% | -0.9% |
| 1Y | -36.5% | -11.8% | 17.7% |
Rendement vs Industrie: CONTX a sous-performé le secteur Norwegian Healthcare Services qui a rapporté -11.8 % au cours de l'année écoulée.
Rendement vs marché: CONTX a sous-performé le marché Norwegian qui a rapporté 17.7 % au cours de l'année écoulée.
Volatilité des prix
| CONTX volatility | |
|---|---|
| CONTX Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 6.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in NO Market | 11.6% |
| 10% least volatile stocks in NO Market | 3.1% |
Cours de l'action stable: CONTX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Norwegian.
Volatilité au fil du temps: La volatilité hebdomadaire de CONTX ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1989 | 43 | Gerald Potzsch | www.contextvision.se |
ContextVision AB (publ), société de logiciels, fournit des services d'analyse d'images et d'imagerie pour les systèmes médicaux en Asie, en Europe et en Amérique. Elle propose des solutions de qualité d'image pour l'échographie, et sa plateforme Rivent comprend Rivent, une amélioration d'image 2D ; Rivent Plus, un produit d'amélioration d'image 2D haut de gamme ; Rivent 3D, une solution pour améliorer la qualité d'image de l'échographie 3D ; et Rivent Mobile, une amélioration d'image 2D pour les appareils portables pour les diagnostics dans divers domaines, y compris la radiologie, la cardiologie, la santé des femmes, la médecine vétérinaire, et les applications de point de soins. La société propose également la plateforme Altumira, qui comporte une correction de la diffusion et améliore la radiographie en permettant de réduire la dose de rayonnement tout en améliorant la qualité de l'image, comme Altumira pour les applications statiques et Altumira Plus pour les applications dynamiques.
ContextVision AB (publ) Résumé des fondamentaux
| CONTX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | NOK 267.49m |
| Bénéfices(TTM) | NOK 4.74m |
| Recettes(TTM) | NOK 113.97m |
48.9x
Ratio P/E2.0x
Ratio P/SLe site CONTX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CONTX compte de résultat (TTM) | |
|---|---|
| Recettes | SEK 113.49m |
| Coût des recettes | SEK 64.90m |
| Marge brute | SEK 48.59m |
| Autres dépenses | SEK 43.88m |
| Les revenus | SEK 4.72m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Aug 27, 2026
| Résultat par action (EPS) | 0.063 |
| Marge brute | 42.82% |
| Marge bénéficiaire nette | 4.16% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CONTX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/09 17:20 |
| Cours de l'action en fin de journée | 2026/06/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
ContextVision AB (publ) est couverte par 3 analystes. 0 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |